Tiziana Life Sciences Ltd (TLSA) Directors and Executive Officers

Officers & Directors

Tiziana Life Sciences Ltd currently has 16 employees.

News about Tiziana Life Sciences Ltd Key Personnel

Tiziana Life Sciences: An Innovative Breakthrough Paves the Way, but Financial Challenges Persist

Tiziana Life Sciences: Innovative Breakthrough and Ongoing Financial Challenges Shape Its Future
In an exciting breakthrough, Tiziana Life Sciences, a renowned biotechnology company, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for its intranasal formulation of foralumab. This formulation, a fully human anti-CD3 monoclonal antibody, is primarily developed to treat non-active Secondary Progressive Multiple Sclerosis (na-SPMS). The recognition from the FDA is a significant milestone for Tiziana, as it signifies the potential of their immunomodulation therapies to revolutionize the field of medicine.
Tiziana s leading development candidate, intranasal foralumab,...

Tiziana Life Sciences Pursues Grant for Clinical Trial of Intranasal Foralumab, Shares Surge Despite Financial Challenges

Tiziana Life Sciences Ltd, a biotechnology company renowned for developing groundbreaking immunomodulation therapies, has recently submitted a grant application to the ALS Association. The Company seeks to secure funding for a clinical trial of its lead development candidate, intranasal foralumab, an innovative fully human anti-CD3 monoclonal antibody. The trial aims to explore the potential of foralumab in the treatment of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that currently lacks effective therapeutic options.
The ALS Association s Hoffman ALS Clinical Trial Awards Program, led by James Berry, MD, MPH, and Suma Babu, MBBS, MS, recognized Tiziana s potential and exte...

Tiziana Life Sciences' Novel Combination Therapy Signals a Promising Path to Combat Obesity-Associated Inflammation

Tiziana Life Sciences, a leading biotechnology company, has made significant strides in their research and development efforts by filing a new patent application for a novel combination therapy. The proposed therapy combines anti-CD3 antibody (Foralumab) with a GLP-1 receptor agonist to target obesity-associated inflammation. This latest development comes at a crucial time for Tiziana Life Sciences, as the company recorded a notable net loss in their recent financial report. Despite these challenges, the company remains committed to finding innovative solutions within the healthcare sector.
Combating Obesity-Associated Inflammation:
Obesity has become a pressing concern around the world, wi...